Strain-related virulence of the dominant Mycobacterium tuberculosis strain in the Canadian province of Manitoba.

Tuberculosis (Edinb)

National Microbiology Laboratory, National Reference Centre for Mycobacteriology, Health Canada, Room H3420 1015 Arlington St, Winnipeg, Manitoba, Canada R3E 3R2.

Published: September 2004

Setting: The Canadian province of Manitoba.

Objective: To confirm the putative hypervirulence observed in Mycobacterium tuberculosis Type1 strain and further characterize the progression and manifestation of pulmonary tuberculosis caused by this strain in comparison to other common clinical isolates from Manitoba.

Design: C3H and BALB/c mice were exposed to aerosols either of Type1, Type2, Type5, Type72 or H37Rv strain to study their respective survival profiles. Additionally, bacillary loads and lung histology were examined at 15 days post-exposure.

Results: In both mouse models, Type-1 infected mice succumbed to disease significantly earlier than other strains (p < or =0.0002). Differences between average log(10) CFU values between clinical isolates were less than 1log(10) difference. In C3H mice, the amount of granulomatous inflammation was highest in Type1 infected mice but not significantly different than all clinical strains. In contrast, BALB/c mice infected with Type1 induced the lowest amount of granulomatous inflammation compared to other clinical isolates.

Conclusion: Our results indicate that although mice infected with the Type1 strain died significantly earlier than mice infected with other clinical strains in both C3H and BALB/c mice, the hypervirulence of the Type1 strain is not attributed to the growth rate of the organism, as differences in growth between clinical M. tuberculosis isolates were insignificant.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tube.2004.01.001DOI Listing

Publication Analysis

Top Keywords

type1 strain
12
balb/c mice
12
mice infected
12
mycobacterium tuberculosis
8
canadian province
8
clinical isolates
8
c3h balb/c
8
mice
8
infected mice
8
amount granulomatous
8

Similar Publications

Pigeon paramyxovirus type-1 (PPMV-1) is the causative agent of pigeon Newcastle disease (ND), which has caused huge losses to the pigeon industry. In this study, a PPMV-1 strain, PPMV-1/QH-01/CH/23, was isolated from a sick racing pigeon in the Qinghai-Tibet Plateau, China in 2023. The mean death time of chicken embryos and the intracerebral pathogenicity index (ICPI) were 76.

View Article and Find Full Text PDF

Introduction: Clinic infections caused by various microorganisms are a public health concern. The rise of new strains resistant to traditional antibiotics has exacerbated the problem. Thus, the search for new antimicrobial molecules remains highly relevant.

View Article and Find Full Text PDF

Engineering an Escherichia coli strain for enhanced production of flavonoids derived from pinocembrin.

Microb Cell Fact

November 2024

Manchester Institute of Biotechnology, Faculty of Science and Engineering, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

Article Synopsis
  • Researchers improved pinocembrin production in E. coli by enhancing the supply of necessary building blocks, achieving 353 mg/L without additional precursor requirements.
  • They found specific enzymes that increased production of related flavonoids, including chrysin and pinostrobin, with the highest yields coming from selected candidate enzymes from different plant sources.
View Article and Find Full Text PDF

Background: Yellow fever (YF), a mosquito-borne acute viral haemorrhagic illness, is endemic to many tropical and subtropical areas of Africa and Central and South America. Vaccination remains the most effective prevention strategy; however, as repeated outbreaks have exhausted vaccine stockpiles, there is a need for improved YF vaccines to meet global demand. A live-attenuated YF vaccine candidate (referred to as vYF) cloned from a YF-17D vaccine (YF-VAX®) sub-strain, adapted for growth in Vero cells cultured in serum-free media, is in clinical development.

View Article and Find Full Text PDF

Combining different drugs synergistically is an essential aspect of developing effective treatments. Although there is a plethora of research on computational prediction for new combination therapies, there is limited to no research on combination therapies in the treatment of viral diseases. This paper proposes AI-based models for predicting novel antiviral combinations to treat virus diseases synergistically.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!